Some of the leading pharma and biotech giants in the Axial Spondyloarthritis (axSpA) therapeutics market include UCB, AbbVie, Pfizer, Amgen, Janssen Biotech, Pozen, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Inmagene Biopharmaceuticals, and others.
DelveInsight’s “Axial Spondyloarthritis (axSpA) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Axial Spondyloarthritis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Axial Spondyloarthritis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Axial Spondyloarthritis: An Overview
Axial spondyloarthritis (axSpA) is a chronic, immune-mediated, inflammatory condition that consists of two subsets, which clinically have been defined as ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Nr-axSpA is characterized by the absence of definitive x-ray evidence of structural damage to the sacroiliac (SI) joint by plain x-ray. Since the SI joint x-ray interpretation is subjective, the distinction between nr-axSpA and AS is not absolute. Sacroiliitis (inflammation of the SI joint) and inflammation of the spine are predominant features of axSpA; hence, patients typically present with inflammatory back pain.
HLA-B27 likely accounts for about 30% of the overall risk, but numerous other genes work in concert with HLA-B27. Researchers have identified more than 60 genes that are associated with Axial Spondyloarthritis and related diseases.
Axial Spondyloarthritis (axSpA) Market Key Facts
The Axial Spondyloarthritis (axSpA) market size in the 7MM was USD 5,594.7 million in 2021.
The total prevalent population of axSpA in the 7MM was 3,981,000+. These cases are anticipated to increase in during the forecast period [2022–2032].
The highest prevalent cases of axSpA were recorded in the US in 2021, making up to 2,217,000+ cases, while the EU5 countries accounted for 1,751,000+ cases in the same year.
Among the different types of genes in axSpA, i.e., HLA-B27, and Others (ERAP 1, IL-12, IL-17, and IL-23), the former accounts for a higher number of diagnosed prevalent cases of axSpA (789622) in the EU-5 in 2021.
As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed in males in comparison to females in all the 7MM countries
Japan had 5,000+ diagnosed prevalent cases of axSpA in 2021, being the lowest of all countries in 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Axial Spondyloarthritis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Axial Spondyloarthritis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Axial Spondyloarthritis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Axial Spondyloarthritis (axSpA) Epidemiology Segmented by –
Total Prevalent Cases of Axial Spondyloarthritis in the 7MM (2019–2032)
Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the 7MM (2019–2032)
Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the 7MM (2019–2032)
Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the 7MM (2019–2032)
Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the 7MM (2019–2032)
Axial Spondyloarthritis (axSpA) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Axial Spondyloarthritis market or expected to be launched during the study period. The analysis covers the Axial Spondyloarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Axial Spondyloarthritis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Axial Spondyloarthritis Market Will Evolve and Grow by 2032 @
Axial Spondyloarthritis (axSpA) Therapeutics Analysis
As per DelveInsight’s assessment, the entry of biosimilars in the market will increase the competition and might hinder both the approved and upcoming therapies if proven to be more effective and potent. It has also been observed that improved regulatory processes allow biosimilars’ approval and make the process easier. Approval of biosimilars will result in a decline in sales, demonstrating the increasing likelihood of high revenue loss following the patent expiry of the already approved drugs. It is also observed that the biosimilar reduces the overall class’s drug pricing and increases product consumption, which will be a challenge to the competitors.
Several major pharma and biotech giants are actively working to develop therapies for Axial Spondyloarthritis. Affibody is leading the therapeutics market with its Axial Spondyloarthritis drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Axial Spondyloarthritis (axSpA) Therapeutics Market Include:
Eli Lilly and Company
Jiangsu HengRui Medicine
Sun Pharmaceutical Industries
Suzhou Zelgen Biopharmaceuticals
And Many More
Axial Spondyloarthritis (axSpA) Drugs Covered in the Report Include:
Bimekizumab: UCB Biopharma
SCB-808: Clover Biopharmaceuticals
Namilumab: Izana Bioscience
Jaktinib: Suzhou Zelgen Biopharmaceuticals
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Axial Spondyloarthritis Competitive Intelligence Analysis
4. Axial Spondyloarthritis Market Overview at a Glance
5. Axial Spondyloarthritis Disease Background and Overview
6. Axial Spondyloarthritis Patient Journey
7. Axial Spondyloarthritis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Axial Spondyloarthritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Axial Spondyloarthritis Unmet Needs
10. Key Endpoints of Axial Spondyloarthritis Treatment
11. Axial Spondyloarthritis Marketed Products
12. Axial Spondyloarthritis Emerging Drugs and Latest Therapeutic Advances
13. Axial Spondyloarthritis Seven Major Market Analysis
14. Attribute Analysis
15. Axial Spondyloarthritis Market Outlook (In US, EU5, and Japan)
16. Axial Spondyloarthritis Access and Reimbursement Overview
17. KOL Views on the Axial Spondyloarthritis Market
18. Axial Spondyloarthritis Market Drivers
19. Axial Spondyloarthritis Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
“Axial Spondyloarthritis Pipeline Insights, 2023” report provides comprehensive insights about 25+ companies and 30+ drugs in Axial Spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States